INDAGLYN RESPICAP 30'S

Indaglyn is used to help control blood sugar levels in adults with type 2 diabetes mellitus. It is prescribed as an add‑on to diet and exercise, either alone or in combination with other antidiabetic medicines, when lifestyle measures alone are not sufficient to achieve adequate glycemic control. It is not indicated for type 1 diabetes or diabetic ketoacidosis.

Indaglyn contains teneligliptin, a DPP‑4 inhibitor. DPP‑4 is an enzyme that breaks down incretin hormones such as GLP‑1 and GIP. By inhibiting DPP‑4, Indaglyn increases the levels and duration of action of these incretins, which enhances glucose‑dependent insulin secretion from the pancreas and reduces glucagon release. This leads to lower blood sugar levels, particularly after meals, with a relatively low risk of hypoglycemia when used without agents that themselves cause low blood sugar.

When used alone, Indaglyn has a relatively low risk of causing hypoglycemia because its action is glucose‑dependent. However, the risk of low blood sugar increases when it is used together with other medicines that can cause hypoglycemia, such as sulfonylureas or insulin. Symptoms of hypoglycemia include sweating, tremor, palpitations, hunger, confusion, and dizziness. Patients should be educated on recognizing and treating low blood sugar and should contact their doctor if episodes are frequent or severe.

Indaglyn should be used with caution in patients with liver impairment. Some DPP‑4 inhibitors have been associated with changes in liver enzymes, and teneligliptin is metabolized in the liver to some extent. Before starting Indaglyn, liver function should be assessed, and periodic monitoring may be recommended, especially in patients with pre‑existing liver disease or those taking other hepatotoxic medicines. If significant elevations in liver enzymes or signs of liver injury such as jaundice, dark urine, or persistent nausea occur, medical evaluation and possible discontinuation of the drug are necessary.

Use of Indaglyn in patients with kidney (renal) impairment requires careful assessment by a healthcare professional. Teneligliptin and its metabolites are eliminated through both hepatic and renal pathways, and the need for dose adjustment or alternative therapy depends on the degree of renal dysfunction and local prescribing guidelines. Patients with moderate to severe kidney disease or those on dialysis should not use Indaglyn without explicit medical supervision. Kidney function tests should be performed periodically, and any changes in renal status should be discussed with the treating physician.

The safety of Indaglyn (teneligliptin) during pregnancy has not been well established, as adequate and well‑controlled studies in pregnant women are lacking. Because of the limited human data, Indaglyn is generally not recommended during pregnancy unless the potential benefit clearly outweighs the potential risk to the fetus, as judged by a specialist. Women who are pregnant, planning to become pregnant, or who suspect they may be pregnant should consult their doctor promptly. Alternative antidiabetic treatments with better‑established safety profiles in pregnancy are usually preferred.

It is not known whether teneligliptin, the active ingredient in Indaglyn, is excreted in human breast milk. Because of the lack of data and the potential for adverse effects in the nursing infant, Indaglyn is generally not recommended during breastfeeding. The decision to continue or discontinue breastfeeding or to continue or discontinue Indaglyn should be made by the healthcare provider, taking into account the importance of the medicine to the mother and the potential risk to the infant. In many cases, an alternative antidiabetic regimen with more established lactation safety may be considered.

Indaglyn itself is not commonly associated with drowsiness or direct impairment of alertness. However, fluctuations in blood sugar, particularly hypoglycemia, can affect concentration, reaction time, and vision, which may impair the ability to drive or operate machinery safely. This risk is higher when Indaglyn is used in combination with other antidiabetic medicines that can cause low blood sugar. Patients should be advised to monitor their blood glucose regularly, be aware of hypoglycemia symptoms, and avoid driving or operating heavy machinery if they feel dizzy, confused, or otherwise unwell.

Alcohol can affect blood sugar control and may either increase or decrease blood glucose levels, depending on the amount consumed and whether it is taken with food. Excessive alcohol intake can increase the risk of hypoglycemia, especially in patients on antidiabetic medications, and can also worsen liver function. While occasional moderate alcohol consumption may be permissible for some patients, it should be discussed with the treating physician. Patients taking Indaglyn should avoid heavy or binge drinking and should monitor their blood sugar more closely if they consume alcohol.

Patients with a known allergy to teneligliptin or any component of Indaglyn should not take this medicine. During treatment, if you develop signs of an allergic reaction such as rash, itching, hives, swelling of the face, lips, tongue, or throat, difficulty breathing, or severe skin reactions, you should stop taking the medicine and seek immediate medical attention. Mild skin reactions should also be reported to your doctor, who will decide whether Indaglyn can be continued or should be discontinued. Always inform your healthcare provider about any history of drug allergies before starting Indaglyn.

Indaglyn is often prescribed in combination with other antidiabetic medicines such as metformin, sulfonylureas, thiazolidinediones, or insulin when additional blood sugar control is needed. Combination therapy should always be guided by a healthcare professional, who will consider the patient’s blood glucose profile, risk of hypoglycemia, kidney and liver function, and other comorbidities. The doses of the accompanying medicines, particularly sulfonylureas or insulin, may need adjustment to reduce the risk of low blood sugar when Indaglyn is added.